Barclays
PMVP icon

Barclays’s PMV Pharmaceuticals PMVP Stock Holding History

Barclays’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.1K Hold
27,536
– – ﹤0.01% 4441
2025
Q4 		$34.4K Hold
27,536
– – ﹤0.01% 4797
2025
Q3 		$38.6K Sell
27,536
-2,661
-9% -$3.68K ﹤0.01% 4831
2025
Q2 		$32K Hold
30,197
– – ﹤0.01% 4776
2025
Q1 		$32.9K Hold
30,197
– – ﹤0.01% 4701
2024
Q4 		$45.6K Sell
30,197
-51
-0.2% -$81 ﹤0.01% 4780
2024
Q3 		$45.1K Sell
30,248
-434,704
-93% -$672K ﹤0.01% 4769
2024
Q2 		$753K Sell
464,952
-28,598
-6% -$51.6K ﹤0.01% 2773
2024
Q1 		$839K Sell
493,550
-23,814
-5% -$44.5K ﹤0.01% 3251
2023
Q4 		$1.6M Buy
517,364
+46,352
+10% +$123K ﹤0.01% 3091
2023
Q3 		$2.89M Buy
471,012
+230,692
+96% +$1.59M ﹤0.01% 1675
2023
Q2 		$1.5M Sell
240,320
-15,602
-6% -$81.8K ﹤0.01% 2066
2023
Q1 		$1.22M Buy
255,922
+93,603
+58% +$659K ﹤0.01% 2580
2022
Q4 		$1.41M Sell
162,319
-31,552
-16% -$336K ﹤0.01% 2522
2022
Q3 		$2.31M Buy
193,871
+71,120
+58% +$1.03M ﹤0.01% 1648
2022
Q2 		$1.75M Buy
122,751
+114,042
+1,309% +$1.66M ﹤0.01% 1950
2022
Q1 		$182K Buy
+8,709
New +$154K ﹤0.01% 3479

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's PMVP Position: Q1 2026 in Review

Barclays held its PMV Pharmaceuticals (PMVP) position steady in Q1 2026 at 27,536 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4441.

Barclays first reported a position in PMVP in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.89M in Q3 2023. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Barclays held 27,536 shares of PMV Pharmaceuticals worth $34.1K as of Q1 2026.
  • Barclays left its PMV Pharmaceuticals share count unchanged in Q1 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4441 holding.
  • Barclays first reported a position in PMV Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's PMV Pharmaceuticals position peaked at $2.89M in Q3 2023.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.